Veritas In Silico Launches First In-House Nucleic Acid Drug Project

An announcement from Veritas In Silico Inc. ( (JP:130A) ) is now available.

Veritas In Silico Inc. has announced the launch of its first in-house pipeline project targeting ischemic acute kidney injury (AKI) induced after cardiovascular surgery, using a first-in-class nucleic acid drug. This strategic move is expected to strengthen the company’s position in the promising nucleic acid drug market, with plans for domestic and global expansion. The company aims to establish cost-effective dosing regimens to improve safety and leverage its expertise to further its pipeline business alongside its collaborative drug discovery efforts.

More about Veritas In Silico Inc.

Veritas In Silico Inc. operates in the pharmaceutical industry, focusing on drug discovery using its proprietary ibVIS® platform. The company specializes in mRNA-targeted small molecule and nucleic acid drug discovery, aiming to address unmet medical needs, particularly in rare diseases.

Average Trading Volume: 42,404

Technical Sentiment Signal: Sell

Learn more about 130A stock on TipRanks’ Stock Analysis page.